Having recently concluded a procurement process for a systematic review and evidence synthesis tool for a regional health authority, I find the current discourse around "rapid" methodologies to be lacking in operational specificity. Promises of speed are ubiquitous, but the actual workflow efficiency, total cost of ownership, and contractual flexibility are seldom detailed. My team was tasked with synthesizing evidence for a non-pharmaceutical intervention policy, under a stringent eight-week deadline, which necessitated a deep evaluation of tools like Elicit against traditional methods.
From a procurement and operational standpoint, "rapid" must be broken down into discrete, measurable phases to assess true vendor capability. Our evaluation focused on:
* **Acceleration in Screening & Data Extraction:** This is where the highest time savings are claimed. We required vendors to demonstrate their tool's performance on a pilot set of 500 previously screened articles. Key metrics were:
* Recall rate at the title/abstract stage (non-negotiable: >99% to avoid missing critical evidence).
* Precision rate improvement over successive rounds of classifier training, directly impacting human reviewer hours.
* Configurability of extraction fields without vendor intervention, to avoid costly professional services add-ons.
* **Total Cost of Ownership (TCO) Beyond Subscription:** The license fee is merely the entry point. A realistic TCO model must include:
* Internal labor costs for platform training and configuration.
* Costs associated with validation of AI-assisted outputs (e.g., time spent checking extracted PICO elements).
* Potential migration costs if the tool proves inadequate for a subsequent project with different requirements, or if the vendor changes pricing models.
* Integration costs with reference managers (e.g., Zotero, EndNote) and data analysis software.
* **Contractual and SLA Considerations:** "Rapid" is meaningless if the tool is unavailable or support is slow. We negotiated service level agreements for:
* Uptime guarantees (with financial penalties) during critical project phases.
* Maximum response times for technical support queries related to workflow blockers.
* Clear data ownership, export, and deletion terms to prevent lock-in and ensure continuity.
In our specific case, tools that offered a rigid, linear workflow became a bottleneck. The ability to iteratively refine questions, re-run searches with modified criteria, and have the platform update the entire downstream evidence matrix was the differentiator for maintaining velocity. Furthermore, we found that vendors offering only annual enterprise contracts created significant risk; we successfully pushed for a pilot project license aligned with our eight-week timeline, with explicit, pre-negotiated terms for extension.
I am interested in reviews from other procurement or project leads who have navigated similar health policy evidence synthesis under time constraints. Concrete details on the following would be invaluable:
* Actual time savings per phase (protocol development, search, screening, extraction) achieved in a real policy project.
* The stability and accuracy of bulk data extraction features over a corpus of 5,000+ PDFs.
* Experiences with negotiating custom, project-based licensing versus standard enterprise subscriptions.
* Any hidden costs encountered during the project lifecycle that were not apparent during the sales demonstration.
-pete
Read the fine print
>Recall rate at the title/abstract stage (non-negotiable: >99% to avoid missing critical evidence).
That's the right metric to focus on, but good luck getting an honest performance guarantee. Most demos use perfectly formatted, recent journal articles. Feed it a batch of older PDFs with poor OCR, grey literature, or non-English abstracts and watch that recall rate plummet.
You're smart to force a pilot on your own data. Even then, the real time sink they never account for is the human validation loop. The tool might flag 200 articles as relevant, but your team still needs to read and confirm each one. If the precision is low, you're just shifting manual work from screening to error-checking. Did any vendor quantify the average time their tool adds per 'hit' for reviewer confirmation? That's the hidden tax on "rapid."
Lisa M.
Your focus on a pilot set of 500 pre-screened articles is the only way to cut through the marketing. We ran a similar exercise last year and found the variance in performance across different public health topics was staggering. A tool trained on RCTs for pharmaceutical interventions often performed poorly when we switched the pilot set to observational studies for environmental health policy, even with retraining. The classifier's starting point matters immensely.
This underscores why contractual flexibility on performance guarantees is so critical. You need the right to exit or renegotiate if the tool's precision on your specific data fails to improve after a set number of training rounds, as you alluded to. Did you manage to codify that kind of milestone-based clause in any of your finalist contracts?
Show the work, not the slide deck.